Showing 2271-2280 of 2527 results for "".
- BTL Files Patent Infringement Lawsuit Against WonderFace Devicehttps://modernaesthetics.com/news/btl-files-patent-infringement-lawsuit-against-wonderface-device/2483957/BTL Group has filed a patent infringement claim before the Unified Patent Court against Lexter Microelectronic Engineering Systems S.L., the company behind the WonderFace device. The claim centers on BTL’s proprietary technology used in its EMFACE system, which integrates selective muscle
- Research Shows Recombinant Pure PDGF Improves Aesthetic Results, Patient Satisfaction Following RF Microneedlinghttps://modernaesthetics.com/news/research-recombinant-pure-pdgf-improves-aesthetic-results-patient-satisfaction-radio-frequency-microneedling/2483898/Research published in the Journal of Cosmetic Dermatology evaluates the efficacy and safety of topical application of pure platelet-derived growth factor (PDGF) compared with standard of care following radiofrequency (RF) microneedling. A prospective, evaluator-blinded, randomize
- Study Finds High-Intensity, Parallel Beam Ultrasound-Based Skin Tightening Effective For Improving Upper Arm Skin Laxity, Crepinesshttps://modernaesthetics.com/news/study-finds-high-intensity-parallel-beam-ultrasound-based-skin-tightening-effective-for-improving-upper-arm-skin-laxity-crepiness/2483859/A study published in Dermatologic Surgery evaluated and compared the efficacy of high-intensity, parallel beam ultrasound-based skin tightening (HIUS) device with microfocused ultrasound with visualization (MFU-V) for the improvement of upper arm skin laxity and crepiness. The pr
- GLP-1 Demand Holds Steady in Aesthetic Clinics Despite Regulatory Shiftshttps://modernaesthetics.com/news/glp-1-demand-holds-steady-in-aesthetic-clinics-despite-regulatory-shifts/2483599/Despite regulatory uncertainty and reported shortages, aesthetic practices continue to experience high demand for glucagon-like peptide-1 (GLP-1) receptor agonists, according to a report released by Guidepoint Qsight on October 1, 2025.
- Hugel Marks 15 Years of Letybo with 2025 H.E.L.F Symposium in Seoulhttps://modernaesthetics.com/news/hugel-marks-15-years-of-letybo-with-2025-helf-symposium-in-seoul/2483385/More than 220 medical professionals from across the globe gathered in Seoul on September 14 for Hugel Inc.’s 2025 H.E.L.F. symposium, marking 15 years since the launch of its botulinum toxin, Letybo. The Hugel Expert Leader’s Forum was held at Seoul Dragon City under the theme, “K-Beau
- Thermage® FLX Exceeds 5 Million Skin Tightening Treatmentshttps://modernaesthetics.com/news/thermage-flx-exceeds-5-million-skin-tightening-treatments/2483284/Solta Medical, a subsidiary of Bausch Health Companies Inc., announced that more than 5 million Thermage® treatments have been performed worldwide, underscoring the global uptake of its skin tightening technology. Thermage® uses monopolar radiofrequency energy to heat skin layers and stimu
- Revance Brings Mepivacaine-Based Fillers to US Markethttps://modernaesthetics.com/news/revance-brings-mepivacaine-based-fillers-to-us-market/2483155/Revance has announced the US launch of the Teoxane RHA® Collection with Mepivacaine, marking a significant innovation in dermal filler formulations. The update reflects a shift in anesthetic agents used in hyaluronic acid fillers, with mepivacaine replacing lidocaine as the primary ane
- Oral GLP-1 Hits Phase 3 Trial Targets; Regulatory Submissions Cominghttps://modernaesthetics.com/news/oral-glp-1-hits-phase-3-trial-targets-regulatory-submissions-coming/2483149/Eli Lilly and Company announced positive topline results from its Phase 3 ATTAIN-2 trial, showing that its investigational oral GLP-1 receptor agonist, orforglipron, achieved significant weight loss and improved cardiometabolic outcomes in adults with obesity or overweight status and type 2 diabe
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://modernaesthetics.com/news/amarte-relaunches-dermatologist-formulated-ultra-veil-daily-spf-40/2483103/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Korean Skincare Brand Launches in US with Sensitive-Skin Formulationshttps://modernaesthetics.com/news/korean-skincare-brand-launches-in-us-with-sensitive-skin-formulations/2483054/South Korean skincare brand Hexkin has entered the US market, offering products formulated for sensitive skin using collagen-based and peptide-driven technologies, according to a press release. Rooted in traditional Korean sk